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infections were more frequent in HIV patients, in particular 
with S. pneumoniae. Tuberculosis was observed in 29 (7.6 %) 
patients, and was also more common in HIV patients. The 
majority of HIV patients was newly diagnosed, and only 15 
(19.5 %) were using combination antiretroviral therapy.
Conclusions Our findings illustrate the impact of HIV co-
infection on the burden of sepsis, malaria and tuberculosis 
in Gabon, as well as the need to scale up HIV counseling, 
testing and treatment.
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Introduction
The HIV epidemic is a major health problem in Africa 
that has changed the spectrum of acute illnesses, such as 
sepsis and malaria, in patients presenting to the hospi-
tal [1, 2]. Sepsis is a heterogeneous condition that can be 
defined by the presence of clinical evidence for infection 
and at least two of four Systemic Inflammatory Response 
Syndrome (SIRS) criteria [3]. Sepsis is an important cause 
of morbidity and mortality worldwide, but detailed infor-
mation on sepsis epidemiology in low- and middle income 
regions is largely unavailable. The immense burden of 
the HIV epidemic in Africa is likely to contribute to the 
number of sepsis cases in this region, as HIV patients are 
more likely to present with bacterial bloodstream infec-
tions (BSIs) [2]. Blood culture is an important diagnostic 
tool in the assessment of a septic patient, but microbiology 
laboratory facilities are often limited in developing regions. 
Therefore, gaining more insight into causative pathogens 
is vital to guide empirical antibiotic treatment. In Central 
Africa, studies on bacterial sepsis have been very limited, 
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and no previous studies were performed in Gabon [4]. The 
HIV prevalence in adults in Gabon was estimated to be 
around 4 % in 2012 [5], and likely influences the spectrum 
of disease in acutely ill patients, including bacterial BSIs 
and sepsis. Other major causes of febrile illness in Gabon 
include malaria which is endemic throughout the country 
and is predominantly caused by Plasmodium falciparum 
[6]. The prevalence of malaria might also be influenced 
by the HIV epidemic. In a systematic review, malaria was 
identified as the third cause of morbidity in HIV patients 
in Africa [7], and HIV infection is associated with an 
increased prevalence of symptomatic malaria, particularly 
in patients with severe immunosuppression [1]. In addition, 
tuberculosis is highly prevalent in central Africa [8], and is 
an important cause of morbidity and mortality in Gabon, 
particularly in HIV-positive patients [9].
With this study, we aimed to determine the influence of 
HIV infection on (1) patient characteristics, including fac-
tors related to health care-seeking behavior, and main diag-
noses in newly admitted patients who present with signs 
of SIRS, (2) the prevalence of bacterial BSI, and causa-




Patients were recruited at the Albert Schweitzer Hospital 
(ASH) in Lambaréné, Gabon, from March 2012 until July 
2013. The ASH is a 150-bed referral hospital in the Moyen 
Ogooué Province and its patients originate from throughout 
central Gabon.
Study design and inclusion criteria
We performed a prospective observational study. All new 
hospital admissions in adults (age ≥18 years) who pre-
sented with fever or hypothermia (tympanic temperature 
≥38 or <36 °C), and at least one other SIRS criterion 
(tachycardia >90/min, respiratory rate >20/min or a white 
blood cell count <4e9 or >12e9 g/L) [10], were eligible for 
participation in the study. The study was conducted accord-
ing to the principles of the Declaration of Helsinki in the 
current version of Seoul, 2008, and was approved by the 
scientific review committee of the “Centre des Recherches 
Medicales de Lambaréné”. Written informed consent was 
obtained from all patients or their guardians prior to enroll-
ment. Aerobic and anaerobic blood cultures, as well as HIV 
and malaria testing, were performed for all participating 
patients. For HIV-positive patients CD4 counts were also 
determined. Patients were included by the study physician 
during weekdays. In addition, blood culture bottles were 
made available to the hospital staff to perform blood cul-
tures at night and during the weekend.
Clinical laboratory methods
Aerobic and anaerobic blood culture vials (Becton–Dickin-
son, Franklin Lakes, NJ, USA) were incubated in the auto-
mated BD Bactec 9050 system for a maximum of 5 days 
or until the culture became positive. Standard culture-based 
methods were used for species identification [API Test stripes 
(bioMérieux, Craponne, France) and BBL Enterotubes or 
BBL Oxi/Ferm Tube (Becton–Dickinson, Franklin Lakes, 
NJ, USA)]. Coagulase-negative staphylococci and Bacillus 
spp. were routinely considered contaminants. Streptococ-
cus viridians were regarded contaminants as well, unless the 
patient had clinical signs of endocarditis or meningitis. As 
part of a clinical trial requirement, the microbiology labora-
tory at the ASH successfully participates in regular external 
quality assurance programs addressing species identification.
For HIV testing, a rapid test was used [Vikia HIV 1/2 
(bioMérieux, Craponne, France), or DetermineTM HIV 1/2, 
(Alere, Yavne, Israel), depending on local availability]. 
In case of a positive reading, the result was confirmed by 
VIDAS HIV DUO Ultra (bioMérieux, Craponne, France) 
and Immunocomb HIV1&2 Bispot (Alere, Yavne, Israel). 
CD4 counts were done using BD FACS count (Becton–
Dickinson, Franklin Lakes, NJ, USA). The Lambaréné 
method to analyze thick smears was applied to diagnose 
malaria [11].
Case definitions
Sepsis cases were defined by clinical evidence of infection 
combined with fever or hypothermia (tympanic tempera-
ture ≥38 or <36 °C) and at least one other SIRS criterion. 
Infection diagnoses were classified on the basis of Centers 
for Disease Control and Prevention and International Sepsis 
Forum Consensus Conference definitions [12–14], adapted 
to the Gabonese situation where limited diagnostic tests 
were available (Online Resource 1: Case definitions for sites 
of infection in sepsis patients). Malaria cases were defined 
as Plasmodium spp. parasitemia (any parasite density) plus 
fever (≥38.0 °C) without another established cause of fever 
(blood culture negative). All patients who were treated 
with antituberculous drugs were classified as tuberculo-
sis patients. In addition, for patients not (yet) on treatment, 
and for classification of the site of infection, we used the 
following definitions: Pulmonary tuberculosis was defined 
by the presence of at least two symptoms (chronic cough 
>2 weeks, night sweats, weight loss or fever) combined with 
a chest X-ray typical for pulmonary tuberculosis, a spu-
tum positive smear by Ziehl–Neelsen or auramine staining. 
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Extrapulmonary tuberculosis was identified by at least two 
symptoms (night sweats, weight loss or fever) combined 
with typical abnormalities on echography (including peripor-
tal or para-aortic lymphadenopathy, splenic microabscesses, 
ascites, pericardial or pleural effusion), on sight during surgi-
cal procedures or in cell compositions of specimens such as 
pleural or pericardial fluid, or by a positive Ziehl–Neelsen or 
auramine staining of an extrapulmonary site.
Statistical methods
Categorical variables are presented as percentages and con-
tinuous variables are presented as medians with their inter 
quartile range (IQR). A Kolmogorov–Smirnov test was 
used to determine the distribution of continuous variables. 
We used χ2 tests for comparisons of categorical variables, 
Mann–Whitney U tests to assess differences in non-nor-
mally distributed continuous variables, and unpaired t tests 
for normally distributed variables. For multivariate analy-
ses of continuous variables, the Kruskal Wallis test was 
used for non-normally distributed variables, and one-way 
ANOVA for normally distributed variables. A p value of 
<0.05 was applied as level of significance in all analyses. 
Data analyses and creation of figures were done with SPSS 
statistics version 19 (IBM, Armonk, NY, USA) and Graph-
Pad Prism (GraphPad Software, La Jolla, CA, USA).
Results
Patient characteristics and main diagnoses
We invited 405 eligible patients to participate in the study. 
Informed consent was obtained from 384 patients. Twenty-
one (5.2 %) patients refused participation to the study, the 
main reason for refusal being unwillingness to be tested for 
HIV. In two patients, blood draw was technically impos-
sible, leaving 382 patients for inclusion in our analyses. 
Of 382 patients, 77 (20.2 %) were HIV positive (Online 
Resource 2: Study flowchart). Our patient population was 
relatively young (median age 34 years, IQR 25–46), with 
a female predominance (n = 240, 63.8 %) (Table 1). HIV 
Table 1  Characteristics of patients admitted to the ASH with acute febrile disease
For categorical variables, the absolute number is given with the percentage, and for continuous variables medians are given with their interquar-
tile range. We used χ2 tests for comparisons of categorical variables, Mann–Whitney U tests to assess differences for non-normally distributed 
continuous variables, and unpaired t tests for normally distributed variables
All p values and odds ratios that breached statistical significance (p  < 0.05) are depicted in bold
OR odds ratio, CI confidence interval
a All malaria cases were caused by Plasmodium falciparum
b Abdominal infections include gastroenteritis, biliary tract infections, peritonitis, appendicitis, endometritis, and intra-abdominal abscesses
c 0.5 was added to each value to allow for calculation of an odds ratio
d Including two cases with both blood culture positive sepsis and pulmonary tuberculosis in one HIV-positive and one HIV-negative patient
Total (n = 382) HIV+ (n = 77) HIV− (n = 305) p value OR (95 % CI)
Demographics
 Age (years) 34 (25–46) 37 (31–45) 33 (23–47) 0.04
 Male sex 142 (37.2) 22 (28.6) 120 (31.4) 0.08 0.62 (0.36–1.06)
 Duration of complaints (days) 3 (2–6) 4 (1–11) 3 (2–5) <0.0001
 Travel time (h) 0.5 (0.3–1.0) 0.5 (0.5–1.6) 0.5 (0.3–1.0) 0.005
Diagnoses
 Malaria 130 (34.1) 14 (18.2) 116 (38.0) 0.001 0.36 (0.19–0.68)
 Malaria parasites/μLa 7200 (1560–24000) 54000 (21990–127200) 5040 (1425–18000) 0.0003
 Sepsis 107 (28.1)b 26 (33.8) 81 (26.6) 0.21 1.41 (0.82–2.41)
 Blood culture positive sepsis 30 (7.9)b 12 (15.6) 18 (5.9) 0.005 2.95 (1.36–6.44)
 Abdominal infectionb 41 (38.3) 5 (19.2) 36 (44.4) 0.02 0.30 (0.10–0.87)
 Pneumonia 22 (20.6) 9 (34.6) 13 (16.0) 0.02 3.45 (1.23–9.66)
 Skin or soft tissue infection 26 (24.3) 8 (30.8) 18 (22.2) 0.38 1.56 (0.58–4.16)
 Urinary tract infection 11 (10.3) 4 (15.4) 7 (8.6) 0.32 1.92 (0.51–7.18)
 Primary bacteremia 7 (6.5) 0 (0.0) 7 (8.6) 0.19 0.17 (0.01–2.97)c
 Tuberculosis 29 (7.6)d 17 (22.1) 12 (3.9) <0.0001 6.92 (3.14–15.24)
 Pulmonary tuberculosis 22 (75.9)d 13 (76.5) 9 (75.0) 0.92 1.08 (0.19–6.06)
 Ziehl–Neelsen or auramine confirmed 13 (44.8) 6 (35.3) 7 (58.3) 0.22 0.39 (0.09–1.78)
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patients were slightly older than HIV-negative patients 
(37 years compared to 33 years, p = 0.04), and had a longer 
duration of complaints prior to presentation [4 days (IQR 
1–11) compared to 3 days (IQR 2–5), p ≤ 0.0001]. The 
majority of patients came from the vicinity of the hospital 
(median travel time 0.5 h, IQR 0.3–1 h), although patients 
with HIV tended to travel farther (median travel time 0.5 h 
(IQR 0.5–1.6 h). HIV patients presented more frequently 
with respiratory symptoms, like cough (39 (50.6 %) ver-
sus 79 (25.9 %) in HIV-negative patients (p < 0.0001)) or 
shortness of breath (29 (37.7 %) and 70 (23.0 %), respec-
tively, p < 0.009)), and weight loss (45 (58.4 %) versus 
47 (15.4 %), respectively, p < 0.0001)) (Online Resource 
3: Clinical symptoms and signs of patients admitted to the 
Albert Schweitzer hospital with acute febrile illness). The 
vast majority of patients were included with fever (median 
temperature 38.9 °C (IQR 38.6–39.0 °C); only 4 (1.0 %) 
patients had hypothermia on admission, and there were 
no differences in temperature according to HIV status. 
Chronic co-morbidities other than HIV infection at the time 
of admission were seen in 49 patients (12.8 %), the most 
important being hypertension (n = 26, 6.8 %), which was 
less common in HIV patients (1.3 % compared to 9.5 %, 
p = 0.02). Other co-morbidities included diabetes mellitus 
(n = 6, 1.6 %), and sickle cell disease (n = 4, 1.0 %).
Malaria was the most frequent diagnosis with 130 
(34.1 %) cases (Table 1). HIV patients were less likely 
to present with malaria (18.2 % compared to 38.0 %, 
p < 0.0001), but when they had malaria, their parasitemia 
was higher (54000/μL compared to 5040/μL, p = 0.001). 
Sepsis was diagnosed in 107 (28.1 %) patients. Pneumo-
nia was more frequent in HIV-positive patients (9 (34.4 %) 
compared to 13 (16.0 %) in HIV-negative patients, 
p = 0.02), while the reverse was true for abdominal 
infections (5 (19.2 %) versus 36 (44.4 %), respectively, 
p = 0.02). Other sites of infection were less frequent and 
were not differentially distributed according to HIV status. 
Positive blood cultures were present in 29 (7.6 %) patients 
and were more often found in HIV-positive patients 
(15.6 % compared to 5.9 %, OR 2.95; 95 % CI 1.36–6.44). 
We found no cases of bacterial BSI combined with Plasmo-
dium parasitemia, but in two cases, one HIV-positive and 
one HIV-negative patient, a bacterial BSI was combined 
with pulmonary tuberculosis. As expected, tuberculosis 
was more frequently diagnosed in HIV-positive patients 
[22.1 versus 3.9 % in HIV-negative patients (OR 6.92; 
95 % CI 3.14–15.24)].
The majority of HIV patients in our cohort were newly 
diagnosed with HIV during participation in the study 
(n = 42, 54.5 %) (Table 2). Among patients whose HIV sta-
tus was already known, 21 (27.3 %) had a history of treat-
ment with combination antiretroviral treatment (cART). 
However, six patients abandoned treatment, so at the time 
of admission only 15 patients (19.5 %) were on cART. 
CD4 counts were available for 68 (88.3 %) patients, and 47 
(69.1 %) of these had advanced disease with CD4 counts 
below 350 cells/mm3. Median CD4 count was 168 cells/
mm3 (IQR 61–738 cells/mm3) and did not differ between 
patients with or without cART, nor between various diag-
nostic categories (Table 2). The patients who abandoned 
treatment suffered from progressive disease with a median 
CD4 count of 48 cells/mm3 (IQR 39–231 cells/mm3).
Data on health care-seeking behavior were avail-
able for 379 (99.2 %) patients (Table 3). The major-
ity (n = 295, 77.8 %) had taken some form of medica-
tion for their current illness prior to presenting at the 
hospital, the most common being analgesics (n = 234, 
79.4 %), antimalarials (n = 79, 26.7 %), and antibiotics 
(57, 19.3 %) (Table 3). Analgesics were more frequently 
used by patients without HIV infection, while antibiot-
ics were taken more often by HIV-infected patients. The 
main sources of medication prior to hospitalization were 
pharmacies (n = 93, 32.7 %), hospitals (n = 84, 29.6 %), 
and dispensaries (n = 36, 12.7 %). Patients with HIV 
Table 2  Characteristics of HIV-
positive patients admitted with 
acute febrile disease
For categorical variables, 
the absolute number is given 
with the percentage, and for 
continuous variables medians 
are given with their interquartile 
range. Multivariate analysis was 
done using the Kruskal–Wallis 
test
cART combination antiretroviral 
therapy, BSI bloodstream 
infection
HIV-positive patients (n = 77) p value
HIV status known prior to admission 35 (45.5) –
Patients with a history of cART 21 (27.3) –
Patients on cART 15 (19.5) –
CD4 count (n = 68) 168 (61–438) –
 CD4 count in patients on cART (n = 14) 273 (41–578) 0.33
 CD4 count in patients with no previous cART (n = 50) 168 (73–458)
 CD4 count in patients who abandoned cART (n = 5) 48 (39–231)
 CD4 count in malaria cases (n = 13) 377 (121–730) 0.26
 CD4 count in sepsis cases (n = 22) 168 (95–398)
 CD4 count in culture confirmed BSI cases (n = 12) 150 (67–198)
 CD4 count in tuberculosis cases (n = 16) 97 (46–158)
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infection had more often visited a hospital prior to presen-
tation (OR 2.88; 95 % CI 1.56–5.29), while HIV-negative 
patients made more use of informal sources of medica-
tion, including friends and local shops (OR 0.17; 95 % CI 
0.04–0.75). Notably, antimalarials and antibiotics were 
only obtained from formal health services like pharma-
cies, dispensaries and hospitals.
Bacterial bloodstream infections
In our prospective cohort of patients included by the study 
physician, culture confirmed true bacterial BSIs were pre-
sent in 30 patients (7.9 %). An additional 84 blood cultures 
were taken by hospital staff in the absence of the study 
physician. Ten of these cultures yielded bacterial growth 
with a pathogenic organism (11.9 %), bringing the total 
number of bacterial isolates to 40. The main isolates were 
Escherichia coli (n = 12, 30.0 %), Staphylococcus aureus 
(n = 6, 15.0 %), and Streptococcus pneumoniae (n = 5, 
12.5 %) (Table 4). When we stratified the causative patho-
gens according to HIV status, we found that S. pneumoniae 
was exclusively present in patients with HIV co-infection 
and this difference was statistically significant (p = 0.003). 
For other pathogens, no statistical differences were found.
Patient outcome
Median length of stay (LOS) in our cohort was 4 days (IQR 
2–6) (Table 5). Malaria patients had the shortest duration 
of stay (3 days, IQR 3–4), sepsis patients stayed longer 
(5 days, IQR 3–8), and patients with tuberculosis had 
the longest LOS (13 days, IQR 9–14). The long duration 
of hospitalization in tuberculosis patients was due to the 
policy that patients should take the first ten days of antitu-
berculous medication under supervision in the hospital. 
Overall mortality in our cohort was low (n = 16, 4.2 %), 
as patients with malaria had only 0.8 % mortality (n = 1). 
Patients with culture confirmed bacterial sepsis had the 
highest mortality of 17.2 % (n = 5). Patients with HIV 
co-infection had a longer LOS (median 5 days (IQR 3–9), 
compared to 4 days (IQR 3–5), p = <0.0001), and mortal-
ity was higher (13 % compared to 2 %). When stratified 
according to the main diagnostic categories, LOS was sig-
nificantly longer for HIV patients with malaria, but not for 
sepsis or tuberculosis. Mortality was higher in HIV patients 
in all diagnostic categories, but the difference did not reach 
statistical significance in the subgroup of culture proven 
sepsis patients and tuberculosis patients, most likely due to 
the small sample size of these groups.
Table 3  Health care-seeking behavior prior to hospitalization
For categorical variables, the absolute number is given with the percentage, and for continuous variables medians are given with their interquar-
tile range. We used χ2 tests for comparisons of categorical variables, Mann–Whitney U tests to assess differences for non-normally distributed 
continuous variables, and unpaired t tests for normally distributed variables
All p values and odds ratios that breached statistical significance (p < 0.05) are depicted in bold
OR odds ratio, CI confidence interval
a Information on medication use prior to hospitalization was missing in 3 cases
b This includes only medication taken within 7 days prior to hospitalization
c Information on source of medication was available for 284 patients (96.3 %). Percentages in this part of the table are calculated using the num-
ber of cases for which data were available as denominator
Total (n = 379) HIV+ (n = 77) HIV− (n = 302)a p value OR (95 % CI)
Medication for current illnessb
 Total 295 (77.8) 56 (72.7) 242 (80.1) 0.1375 0.65 (0.36–1.15)
 Analgesics 234 (79.4) 35 (62.5) 200 (82.3) 0.0011 0.36 (0.19–0.68)
 Antimalarials 79 (26.7) 11 (19.6) 68 (28.0) 0.2408 0.63 (0.31–1.29)
 Antibiotics 57 (19.3) 20 (35.7) 37 (15.2) 0.0004 3.1 (1.6–5.9)
 Other 19 (6.4) 7 (12.5) 12 (4.9) 0.0365 2.75 (1.03–7.34)
Source of medicationc
 Pharmacy 93 (32.7) 14 (25.9) 79 (33.9) 0.1927 0.63 (0.32–1.25)
 Hospital 84 (29.6) 26 (46.4) 58 (24.9) 0.0005 2.88 (1.56–5.29)
 Other hospital 55 (19.4) 18 (32.1) 37 (15.9) 0.0033 2.65 (1.36–5.16)
 Study hospital 29 (10.2) 8 (14.3) 21 (9.0) 0.1644 1.85 (0.77–4.47)
 Dispensary 36 (12.7) 7 (12.5) 28 (12.4) 0.8482 1.09 (0.61–3.67)
 Traditional medicine 5 (1.8) 1 (1.8) 3 (1.3) 0.7462 1.46 (0.45–2.65)
 Various informal 44 (15.5) 2 (3.7) 42 (18.0) 0.0085 0.17 (0.04–0.75)
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Discussion
We demonstrated that HIV co-infection has a major impact 
on the causes and outcome of acute febrile illness requiring 
hospitalization in Gabon. In malaria patients, HIV co-infec-
tion was associated with higher parasitemia, longer LOS 
in hospital, and higher mortality. In accordance, previous 
studies found increased severity of disease and impaired 
response to treatment in HIV-positive malaria patients [1]. 
This could be due to defects in the innate immune response 
to malaria, as natural killer, natural killer T, and γδ T-cells, 
isolated from the peripheral blood of HIV patients, were 
recently shown to be less responsive to a challenge with 
P. falciparum parasites [15]. The prevalence of malaria 
Table 4  Main causative pathogens of bacterial bloodstream infection and their distribution according to HIV status
For all variables, the absolute number is given with the percentage. χ2 tests were used for comparisons between HIV-positive and HIV-negative 
cases
All p values and odds ratios that breached statistical significance (p < 0.05) are depicted in bold
OR odds ratio, CI confidence interval
a Including one case with an unknown HIV status
b 0.5 was added to each value to allow for calculation of an odds ratio
c Including group B (3), group C (3), and group D (2) streptococci. The single HIV-positive patient in this group was infected with a group C 
streptococci
Total (n = 40) HIV+ (n = 15) HIV− (n = 23) p value OR (95 % CI)
Escherichia coli 12 (30.0)a 3 (20.0) 8 (34.8) 0.33 0.47 (0.10–2.16)
Staphylococcus aureus 6 (15.0)a 3 (20.0) 2 (8.7) 0.31 2.63 (0.38–18.00)
Streptococcus pneumoniae 5 (12.5) 5 (33.3) 0 (0.0) 0.003 24.62 (1.24–487.5)b
Salmonella typhi 2 (5.0) 0 (0.0) 2 (8.7) 0.24 0.28 (0.01–6.20)b
Non-typhoidal salmonellae 2 (5.0) 2 (13.3) 0 (0.0) 0.09 7.58 (0.34–169.0)b
Klebsiella pneumoniae 1 (2.5) 0 (0.0) 1 (4.3) 0.41 0.48 (0.02–12.68)b
Serratia marcescens 1 (2.5) 0 (0.0) 1 (4.3) 0.41 0.48 (0.02–12.68)b
Streptococcus viridans 1 (2.5) 1 (6.7) 0 (0.0) 0.21 4.86 (0.19–127.6)b
Neisseria meningitidis 1 (2.5) 0 (0.0) 1 (4.3) 0.41 0.48 (0.02–12.68)b
Bacteroides spp. 1 (2.5) 0 (0.0) 1 (4.3) 0.41 0.48 (0.02–12.68)b
B-Hemolytic streptococcic 8 (25.0) 1 (8.3) 7 (30.4) 0.08 0.16 (0.02–1.50)
Table 5  Patient outcome
For categorical variables, the absolute number is given with the percentage, and for continuous variables medians are given with their interquar-
tile range. We used χ2 tests for comparisons of categorical variables, Mann–Whitney U tests to assess differences for non-normally distributed 
continuous variables, and unpaired t tests for normally distributed variables
All p values and odds ratios that breached statistical significance (p < 0.05) are depicted in bold
OR odds ratio, CI confidence interval, BSI bloodstream infection
a 0.5 was added to each value to allow for calculation of an odds ratio
Total (n = 382) HIV+ (n = 77) HIV− (n = 305) p value OR (95 % CI)
Length of stay (days)
 Total 4 (2–6) 5 (3–9) 4 (3–5) <0.0001
 Malaria 3 (3–4) 4 (4–6) 3 (3–4) 0.001
 Sepsis 5 (3–8) 5 (3–10) 5 (3–7) 0.63
 Culture proven sepsis 5 (3–9) 8 (3–12) 4 (3–7) 0.10
 Tuberculosis 13 (9–14) 11 (5–15) 13 (10–14) 0.84
In hospital mortality
 Total 16 (4.2) 10 (13.0) 6 (2.0) <0.0001 7.43 (2.61–21.18)
 Malaria 1 (0.8) 1 (7.1) 0 (0.0) 0.005 24.10 (0.94–620.2)a
 Sepsis 7 (6.5) 4 (15.4) 3 (3.7) 0.04 4.73 (0.98–22.73)
 Culture proven BSI 5 (17.2) 3 (25.0) 2 (11.8) 0.35 2.50 (0.35–17.95)
 Tuberculosis 3 (11.1) 3 (18.8) 0 (0.0) 0.13 5.96 (0.28–128.0)a
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in our cohort was high (34.1 %), and our figures are even 
likely to present an underestimation as use of antimalarial 
drugs prior to hospitalization was common. HIV infection 
was previously described as a risk factor for symptomatic 
malaria [1], so the HIV epidemic in Gabon may drive an 
increase in adult malaria cases. As malaria infection was 
even more frequent in HIV-negative patients (38 %), other 
factors are likely adding to the burden of malaria. Recent 
evidence indicates that malaria is an underrecognized 
driver of adult mortality in Africa [16], and one possibility 
is that the successful roll-out of malaria intervention strate-
gies targeted at children and pregnant women has shifted 
the burden of disease to non-pregnant adults [17, 18].
Sepsis was an important reason for admission in HIV-
positive patients (33.8 %), and HIV-negative patients 
(26.6 %). In line with previous studies, HIV co-infection 
was associated with an increased prevalence of bacterial 
BSI in patients with sepsis, and enhanced sepsis-related 
mortality [2]. The relatively low overall prevalence of 
bacterial BSI in this cohort compared to that reported in a 
systematic review for African countries (7.6 % compared 
to 13.5 %) may be related to the fact that our population 
was relatively young and had few chronic co-morbidities. 
In accordance with previous studies [2, 4], we found E. 
coli, S. aureus and S. pneumoniae to be the main isolates in 
patients with BSI, and our study confirms an increased risk 
for S. pneumoniae BSI in HIV-positive patients, a pathogen 
that is known to frequently cause invasive disease in HIV 
patients [4, 19]. Bloodstream infection with non-typhoidal 
Salmonella, a pathogen also known to be more common 
in patients with HIV co-infection [2, 20], was exclusively 
found in HIV-positive patients, but the number of cases 
was too small to demonstrate a significant difference with 
HIV-negative patients. Pathogenic mechanisms that may 
be related to increased prevalence and severity of bacterial 
sepsis were recently reviewed, and include defects in both 
innate and adaptive immunity [21].
Tuberculosis is an important cause of morbidity and 
mortality in HIV patients [22]. In accordance, we observed 
a higher prevalence of tuberculosis in HIV-positive patients 
(22.1 % compared to 3.9 %). Key factors for the increased 
susceptibility of HIV patients to develop tuberculosis 
include general as well as Mycobacterium tuberculosis spe-
cific CD4 T cell depletion [22]. In comparison to a previ-
ous retrospective survey of tuberculosis in the same hos-
pital, which registered an annual number of around 120 
tuberculosis cases [9], the number of tuberculosis patients 
in this study is low (n = 29). A possible explanation for 
this difference is that the majority of hospitalized tubercu-
losis patients do not present with acute febrile illness, but 
rather are admitted with chronic complaints. The higher 
rate of HIV co-infection in tuberculosis patients in our 
cohort (58.6 %), compared to 28.5 % in the previous study 
[9], suggests that HIV patients with tuberculosis are more 
prone to present with an acute sepsis-like illness.
Non-prescription antibiotic use is common in Africa and 
is a driver of antimicrobial resistance [23]. In our cohort, 
19.3 % used antibiotics prior to hospitalization, but the 
majority of patients obtained their drugs from a previous 
visit to the hospital, indicating that the use of over-the-
counter antibiotics is limited in Gabon. In HIV patients, 
the use of antibiotics for their current illness prior to hos-
pitalization was higher, which was most likely related to 
increased severity and longer duration of illness. These 
patients were also more likely to have visited a hospital for 
their complaints prior to their hospitalization. Antimalarial 
drugs were more commonly used prior to hospitalization 
(26.7 % of cases with no difference according to HIV sta-
tus) and were mostly bought in the pharmacy. These figures 
are low in comparison to other African countries, such as 
Nigeria, where a survey found 100 % of antibiotics used 
were obtained without prescription [23]. The use of tradi-
tional medicine was previously reported to be very com-
mon in Gabonese patients with tuberculosis [24], and is 
also frequently observed in HIV patients in other African 
countries [25, 26]. However, in our study the use of tradi-
tional medicine was limited to 1.8 % of patients, with no 
differences according to HIV status. One explanation for 
the discrepancy is that traditional medicine is mostly used 
in the case of chronic illness, whereas our patients gener-
ally presented to the hospital with acute illness. In addition, 
patients may be reluctant to discuss the use of traditional 
medicine in a formal health care setting like the hospital.
Our data illustrate the burden of HIV infection in this 
region and gaps in HIV testing and treatment. The major-
ity of HIV patients (69.1 %) presented with advanced dis-
ease with CD4 counts below 350 cells/mm3, the current 
World Health Organization threshold for prioritizing the 
start of cART [27]. However, only 19.5 % of HIV patients 
were using treatment at the time of admission. The need 
for increased availability of HIV counseling and testing 
is illustrated by the fact that more than half (54.5 %) of 
the HIV patients in our cohort were newly diagnosed. In 
addition, the finding that 20.2 % of patients in our cohort 
were HIV positive illustrates that implementation of rou-
tine counseling and testing for hospitalized patients would 
be beneficial. In other African countries, provider-initiated 
testing and counseling proved to be very useful in increas-
ing the number of patients tested and in reaching patients 
who perceived themselves to be at low risk [28, 29]. 
Although patient acceptance was variable in other settings 
[28], our study demonstrates a high level of acceptance 
for HIV testing among Gabonese patients. However, chal-
lenges exist in linking newly diagnosed patients to care and 
retaining them in care. Previous studies in Gabon and other 
settings demonstrated a high level of loss to follow-up in 
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HIV patients and we also found that a significant propor-
tion of patients who previously used treatment abandoned 
cART (n = 6, 28.6 %) [29].
There are some limitations of this study that need to be 
mentioned. First, due to limited availability of diagnostic 
tools, we were unable to provide a conclusive diagnosis for 
the entire cohort. Possible diagnoses in febrile patients who 
did not meet our criteria for malaria, sepsis or tuberculosis 
include viral illnesses, such as dengue or chikungunya, both 
of which have been previously reported in Gabon [30] as 
well as malaria episodes masked by previous treatment. In 
addition, as the study was not primarily designed to inves-
tigate tuberculosis, the indication for tuberculosis diagnos-
tic tests was left to the treating physician. Tuberculosis was 
principally diagnosed by Ziehl Neelsen staining of spu-
tum, or on clinical grounds, as alternative diagnostic means 
such as culture or PCR were not available. This may have 
resulted in an underestimation of the number of tuberculosis 
cases in this cohort. Third, we performed a hospital-based 
study, so our findings may not be representative for causes 
of morbidity and mortality in the community. Although the 
Albert Schweitzer Hospital is a regional referral hospital, 
the vast majority of patients came from the vicinity of the 
hospital, which suggests that patients in remote areas with 
limited infrastructure, particularly those with more severe 
disease, may not be able to reach the hospital.
Conclusion
In African countries like Gabon, the HIV epidemic has a 
major influence on the prevalence, severity and outcome of 
acute febrile illness due to sepsis, malaria or tuberculosis. 
This study is the first to systematically investigate bacterial 
BSIs and sepsis in Gabon, and illustrates the importance of 
microbiology laboratory facilities, in particular for HIV 
patients who present more frequently with bacterial BSI. In 
addition, we identified a large gap between the number of 
HIV patients in need of cART, and those who know their HIV 
status and receive proper treatment or care, representing an 
important challenge in the management of HIV in this region.
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